WCC recently participated in the Taiwan Urologist Association (TUA) gathering at Kuang Tien General Hospital, an event bringing together renowned urologists and industry experts from
WCC Biomedical announced an remarkable achievement as its next-generation pain-relief product WCC-301 successfully completed the US FDA Pre-IND meeting and has now entered GLP toxicology studies,
As Taiwan’s leading researcher and manufacturer of microarray patches (MAPs), we were honored to be invited as a featured speaker at StartUp@Taipei, held in Osaka,
Following the success of Bio-Asia 2025, WCC is moving forward to further showcase our innovations in the healthcare field. We are driving change not only
From May 11 to 14, 2025, WCC Biomedical had the privilege of participating as featured speakers and an exhibitor at the Microneedles Conference 2025, held
The BARDA’s Vaccine Innovation Forum is a prestigious event hosted by the Biomedical Advanced Research and Development Authority (BARDA) to celebrate and announce the winner